We are a drug discovery company selectively targeting protein myristoylation for the treatment of a wide range of diseases including cancer and viral infections.
Based on our world leading research into the structure and biology of N-myristoyltransferase (NMT), the key enzyme in protein myristoylation we have made highly potent and selective small molecule inhibitors of this enzyme.
Led by a team of internationally renowned scientists and drug developers with an outstanding track record of commercial and academic successes.
To unlock the potential of N-myristoyltransferase (NMT) as a therapeutic target and develop precision medicines for a range of diseases with unmet medical need including cancer and viral infections.
High-resolution snapshots of human N-myristoyltransferase in action
- Myricx Pharma Announces Senior Team Expansion with Appointment of CMO, and Heads of Biology and Bioinformatics 22 February 2022 - Zahid Bashir MB BS, MSc joins as Chief Medical Officer, bringing significant clinical haematology and oncology experience, having led the…
- Myricx Pharma Announces Board and Executive Appointments 20 April 2021 - Rachael Brake, PhD joins the board as independent non-executive director, bringing significant drug development experience, notably from Takeda, Amgen, Millennium…